Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kyverna Therapeutics, Inc. (Nasdaq: KYTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Kyverna is a clinical-stage biopharmaceutical company focused on CD19-targeting CAR T-cell therapies for autoimmune diseases, and its filings offer detailed information on clinical progress, financing arrangements, and governance matters.
Investors can review Form 8-K current reports in which Kyverna describes material events such as positive topline data from the KYSA-8 registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff person syndrome, interim Phase 2 data from the KYSA-6 registrational trial in generalized myasthenia gravis, and guidance on anticipated regulatory steps like a planned Biologics License Application for SPS. Other 8-K filings outline a loan and security agreement with Oxford Finance LLC, the terms of an underwritten public offering of common stock under an effective Form S-3 shelf registration statement, and leadership changes including the appointment of an Executive Chairperson of the Board.
Through this page, users can also locate references to Kyverna’s status as an emerging growth company, details on its Nasdaq-listed common stock under the ticker KYTX, and exhibits such as underwriting agreements, legal opinions, and investor presentations. Stock Titan’s interface surfaces these filings as they are made available on EDGAR and pairs them with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing all of the legal language.
For those researching KYTX, this filings hub is a central resource for tracking Kyverna’s reported clinical milestones, financial obligations, equity offerings, and board-level decisions as disclosed in its SEC submissions.
Kyverna Therapeutics Executive Chairperson Shaw Christi reported new equity awards from the company. On January 12, 2026, Shaw Christi received 30,000 shares of common stock as a restricted stock unit award, which vests in four equal annual installments starting January 12, 2027, subject to continued service.
She also received 24,301 performance restricted stock units that vest only if Kyverna’s common stock reaches specified share price targets. In addition, she was granted a stock option for 185,000 shares of common stock at an exercise price of $8.23 per share, with one quarter vesting on January 12, 2027 and the remainder vesting monthly thereafter, conditioned on continued service. Following these awards, she beneficially owned 70,935 shares of common stock and 185,000 stock options directly.
Kyverna Therapeutics appointed Christi Shaw as Executive Chairperson of its Board, effective January 12, 2026. She will replace Ian Clark as Chairperson, who will continue to serve as a director. Shaw will be employed on an at-will basis with an initial annual salary of $400,000.
As part of her compensation, Shaw will receive an option to purchase 185,000 shares of common stock and 30,000 restricted stock units, each vesting over four years, along with performance RSUs equal to $200,000 divided by the grant-date fair market value, which vest upon achieving specified stock price targets. If a change in control occurs during her employment, all of her unvested equity awards will fully vest, with performance targets deemed achieved at the target level.
The company also furnished a press release providing a corporate update, strategic priorities for 2026, and preliminary unaudited financial information for the year ended December 31, 2025, which may change upon completion of year-end procedures.
Kyverna Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 13,333,333 shares of common stock at a public offering price of $7.50 per share. Underwriters will purchase the shares at $7.05 per share and have a 30-day option to buy up to an additional 1,999,999 shares at the public offering price, less underwriting discounts and commissions.
The company expects gross proceeds of approximately $100 million, before deducting underwriting discounts, commissions and offering expenses. Kyverna intends to use the net proceeds for general corporate purposes, which may include funding research and development, capital expenditures, working capital and general and administrative expenses. Closing is expected on or about December 18, 2025, subject to customary conditions, and directors, executive officers and certain affiliated stockholders are subject to lock-up agreements generally through January 31, 2026.
Kyverna Therapeutics, Inc. is issuing 13,333,333 shares of common stock at $7.50 per share in a primary offering on the Nasdaq Global Select Market under the symbol KYTX. Underwriters have a 30-day option to buy up to an additional 1,999,999 shares at the same price, less underwriting discounts and commissions of $0.45 per share. Gross proceeds are approximately $99.999 million, with estimated net proceeds of about $93.7 million, or $107.8 million if the option is fully exercised.
The company plans to use the cash, together with existing cash and cash equivalents, prior at-the-market sales of $16.9 million and loan proceeds, for general corporate purposes including research and development, capital expenditures, working capital and administrative costs. Management believes this funding will support operations through 2028 and back a planned biologics license application for stiff person syndrome and a Phase 3 trial in generalized myasthenia gravis.
Kyverna is a clinical-stage cell therapy company focused on autoimmune diseases, led by its CD19 CAR T candidate mivocabtagene autoleucel (miv-cel). Recent registrational Phase 2 data in stiff person syndrome showed functional gains, sustained freedom from immunotherapies and no high-grade CRS or ICANS, with Grade 3/4 neutropenia reported in 62% of patients and described as manageable.
Kyverna Therapeutics' chief technology officer reported an option exercise and share sale in Kyverna Therapeutics, Inc. common stock. On 12/15/2025, the officer exercised stock options to acquire 23,998 shares at an exercise price of $4.83 per share and, on the same date, sold 23,998 shares at $12.2 per share. After these transactions, the officer beneficially owned 22,636 shares of common stock directly and held 85,865 stock options.
The filing states that these trades were made under a Rule 10b5-1 trading plan adopted on September 12, 2025, which automates transactions according to preset instructions. The option originally vested 25% of the shares on January 1, 2025, with the remaining portion vesting in equal monthly installments, contingent on continued service.
Kyverna Therapeutics is offering $100,000,000 of common stock, with underwriters holding a 30-day option to buy up to an additional $15.0 million of shares. The clinical-stage company develops CD19 CAR T-cell therapies for autoimmune diseases, led by its autologous candidate mivocabtagene autoleucel (miv-cel). It plans to use net proceeds, together with existing cash, for general corporate purposes including research and development, and states that, combined with prior at-the-market sales and loan proceeds, this financing is expected to fund operations through 2028 and support a planned BLA filing in stiff person syndrome (SPS) and a Phase 3 trial in myasthenia gravis (MG).
Kyverna recently reported positive topline data from the registrational KYSA-8 Phase 2 SPS trial in 26 patients: among 12 patients who needed a walking aid before treatment, 67% no longer required assistance at Week 16; 100% remained off immunotherapies without rescue therapy at last follow-up. Miv-cel was described as well-tolerated, with no high-grade CRS or ICANS and Grade 3/4 neutropenia in 62% of patients, which was reported as manageable and resolved.
Kyverna also highlights a non-dilutive term loan facility of up to $150.0 million with Oxford Finance. It has drawn $25.0 million, and the positive KYSA-8 data made an additional tranche of up to $20.0 million available, bringing currently available undrawn funding to $35.0 million. The company cautions that investing in its stock involves a high degree of risk, including dilution from this offering, potential future equity issuances, broad discretion over proceeds and significant stock price volatility.
Kyverna Therapeutics, Inc. announced positive topline data from KYSA-8, a registrational Phase 2 trial of its fully human, autologous CD19 CAR T-cell therapy mivocabtagene autoleucel (miv-cel, formerly KYV-101) in stiff person syndrome.
The company is hosting a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results and has provided an investor slide presentation as Exhibit 99.1, which is furnished rather than filed under federal securities law provisions.
Kyverna Therapeutics reported positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome.
The company also stated it will host a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results, and made a detailed press release available describing the KYSA-8 data and its implications for the miv-cel program.
Kyverna Therapeutics (KYTX) filed its Q3 2025 10‑Q. The company reported a net loss of
Liquidity remained solid with cash, cash equivalents and marketable securities of
Management estimates that, with the initial
Kyverna Therapeutics, Inc. (KYTX) furnished an 8-K announcing it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report was signed by Chief Financial Officer Marc Grasso, M.D.
FAQ
What is the current stock price of Kyverna Therapeutics (KYTX)?
What is the market cap of Kyverna Therapeutics (KYTX)?
